SYK

NYSE · Health Care

Stryker Corp

Q: What does Stryker Corporation do?

Stryker manufactures orthopedic implants, surgical instruments, and medical equipment used in hospitals and surgical centers worldwide. The company produces hip and knee replacement systems, spinal devices, surgical navigation technology, and hospital beds. Revenue comes from implant sales, capital equipment purchases, and recurring instrument servicing contracts. Stryker operates through direct sales representatives calling on orthopedic surgeons and hospital procurement departments.

Q: Is SYK stock a good investment?

Stryker has delivered consistent revenue growth driven by aging demographics and increasing joint replacement procedures. The company maintains high gross margins on proprietary implant systems and invests heavily in R&D for robotic surgery platforms. Risks include pricing pressure from hospitals, device recalls, and competition from lower-cost manufacturers. Exposure to elective procedures makes revenue sensitive to hospital volumes and reimbursement changes.

Q: Who are Stryker Corporation's main competitors?

Zimmer Biomet competes directly in orthopedic implants and joint reconstruction with similar product portfolios. Johnson & Johnson (through DePuy Synthes) challenges across orthopedics and surgical devices. Medtronic competes in spinal implants and surgical navigation. Smith & Nephew contests in sports medicine and trauma devices, while smaller firms compete in specific orthopedic niches.

Q: Does Stryker Corporation pay dividends?

Stryker has increased its dividend for over 30 consecutive years, earning dividend aristocrat status. The company maintains a low payout ratio allowing substantial reinvestment in product development and acquisitions. Management has grown the dividend faster than earnings in recent years while also executing share buybacks.

Q: What is the current share price of SYK?

SYK last closed at $328.51, down 1.23% in the most recent trading session. Over the past 52 weeks, the stock has traded between a low of $328.23 and a high of $404.87. The current price represents 0% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.

Q: Is SYK rated a buy or sell by analysts?

Among 37 analysts covering SYK, the consensus rating is Strong Buy — 28 rate it a buy, 9 hold, and 0 sell. The average price target sits at $338.36, implying 3% upside from the current price. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.

Q: What are Stryker Corp's earnings?

Stryker Corp generated $24.83B in revenue during fiscal year 2026, with $3.21B reaching the bottom line as net income. The net profit margin of 12.9% is solid for its sector.

Q: How is SYK valued compared to earnings?

SYK trades at a P/E ratio of 39.52 on trailing earnings of $8.40 per share. That's above the S&P 500 historical average, suggesting the market expects above-average earnings growth ahead. Comparing this multiple against Health Care sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.

S&P 500 Large-Cap Stocks Blue Chip Stocks Healthcare Stocks Best Dividend Stocks

$328.51

-4.08 (-1.23%)

As of Mar 24, 9:31 PM ET ·

Day Range $327.21 — $331.62

52W Range $328.23 — $404.87

Performance

1D —

1W —

1M —

3M -7.26%

6M -10.98%

1Y -11.90%

YTD -5.65%

Open$331.22

Previous Close$332.59

Day High$331.62

Day Low$327.21

52W High$404.87

52W Low$328.23

Volume—

Avg Volume2.49M

Market Cap128.28B

P/E Ratio39.52

EPS$8.40

SectorHealth Care

Technical Indicators

Full analysis →

SMA 50 $359.01 Below

SMA 200 $374.71 Below

RSI (14) 65.8 Neutral

Trend Death Cross Bearish

Analyst Ratings

Strong Buy

37 analysts

28 Buy 9 Hold 0 Sell

Price Target +3.0% upside

Current
$328.51

Target
$338.36

$217.23 $338.36 avg $444.41

Key Financials

	FY 2026	FY 2025	FY 2024
Revenue	24.83B	22.41B	43.49B
Net Income	3.21B	2.61B	8.24B
Profit Margin	12.9%	12.3%	18.9%
EBITDA	5.67B	4.86B	9.81B
Free Cash Flow	—	—	3.51B
Rev Growth	+10.8%	+10.8%	+22.5%
Debt/Equity	0.71	0.71	0.52

Dividend

Dividend Yield1.04%

Annual Dividend$3.36

Payout Ratio39.6%

Frequencyquarterly

Ex-DividendMar 22, 2026

Pay DateApr 8, 2026

Recent Insider Activity

All Insiders →

Date	Insider	Type	Shares	Price	Value
Feb 6	STRYKER RONDA E	Sale	2,692,894	$358.51	$965.43M
Feb 6	STRYKER RONDA E	Sale	2,678,221	$359.48	$962.77M
Feb 6	STRYKER RONDA E	Sale	2,637,858	$360.41	$950.72M
Feb 6	STRYKER RONDA E	Sale	2,612,638	$361.39	$944.17M
Feb 6	STRYKER RONDA E	Sale	2,582,571	$362.69	$936.67M

About Stryker Corp

Stryker Corporation, based in Michigan, is a global medical device and surgical equipment manufacturer serving hospitals, clinics, and healthcare providers. The company produces orthopedic devices, surgical instruments, neurotechnology products, and hospital beds.

Health Care Peers

Symbol	Name	Price	Change	P/E	Mkt Cap
UNH	UnitedHealth Group Inc	$272.28	+1.02%	21.7	261.12B
ABT	Abbott Laboratories	$105.30	+1.19%	28.3	184.68B
ISRG	Intuitive Surgical Inc	$470.18	-0.37%	59.8	170.78B
MDT	Medtronic Plc	$86.58	-0.68%	24.1	111.30B
MCK	Mckesson Corp	$880.70	-0.14%	25.1	109.03B
HCA	Hca Healthcare Inc	$483.52	-0.45%	16.5	111.74B

SYK News

Boston Scientific Shares Extend Decline Amid Electrophysiology Concerns

Feb 9

Quick Stats

Market Cap128.28B

P/E Ratio39.52

EPS$8.40

Div Yield1.04%

Volume—

SectorHealth Care

SYK Frequently Asked Questions

What does Stryker Corporation do?

Stryker manufactures orthopedic implants, surgical instruments, and medical equipment used in hospitals and surgical centers worldwide. The company produces hip and knee replacement systems, spinal devices, surgical navigation technology, and hospital beds. Revenue comes from implant sales, capital equipment purchases, and recurring instrument servicing contracts. Stryker operates through direct sales representatives calling on orthopedic surgeons and hospital procurement departments.

Is SYK stock a good investment?

Stryker has delivered consistent revenue growth driven by aging demographics and increasing joint replacement procedures. The company maintains high gross margins on proprietary implant systems and invests heavily in R&D for robotic surgery platforms. Risks include pricing pressure from hospitals, device recalls, and competition from lower-cost manufacturers. Exposure to elective procedures makes revenue sensitive to hospital volumes and reimbursement changes.

Who are Stryker Corporation's main competitors?

Zimmer Biomet competes directly in orthopedic implants and joint reconstruction with similar product portfolios. Johnson & Johnson (through DePuy Synthes) challenges across orthopedics and surgical devices. Medtronic competes in spinal implants and surgical navigation. Smith & Nephew contests in sports medicine and trauma devices, while smaller firms compete in specific orthopedic niches.

Does Stryker Corporation pay dividends?

Stryker has increased its dividend for over 30 consecutive years, earning dividend aristocrat status. The company maintains a low payout ratio allowing substantial reinvestment in product development and acquisitions. Management has grown the dividend faster than earnings in recent years while also executing share buybacks.

What is the current share price of SYK?

SYK last closed at $328.51, down 1.23% in the most recent trading session. Over the past 52 weeks, the stock has traded between a low of $328.23 and a high of $404.87. The current price represents 0% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.

Is SYK rated a buy or sell by analysts?

Among 37 analysts covering SYK, the consensus rating is Strong Buy — 28 rate it a buy, 9 hold, and 0 sell. The average price target sits at $338.36, implying 3% upside from the current price. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.

What are Stryker Corp's earnings?

Stryker Corp generated $24.83B in revenue during fiscal year 2026, with $3.21B reaching the bottom line as net income. The net profit margin of 12.9% is solid for its sector.

How is SYK valued compared to earnings?

SYK trades at a P/E ratio of 39.52 on trailing earnings of $8.40 per share. That's above the S&P 500 historical average, suggesting the market expects above-average earnings growth ahead. Comparing this multiple against Health Care sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.

What is SYK's return over the past year?

Performance varies across timeframes, reflecting shifting market conditions. Returns by timeframe: -7.26% (3M), -10.98% (6M), -11.90% (1Y), -5.65% (YTD). Comparing these figures against the S&P 500 and sector benchmarks helps determine whether SYK is outperforming or lagging the broader market.